Brainstorm Cell Therapeutics - BCLI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.62
▲ +0.05 (8.77%)

This chart shows the closing price for BCLI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Brainstorm Cell Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BCLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BCLI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Brainstorm Cell Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.62.

This chart shows the closing price for BCLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 contributing investment analysts is to hold stock in Brainstorm Cell Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/28/2023Maxim GroupDowngradeBuy ➝ HoldLow
3/31/2023Maxim GroupBoost TargetBuy$5.00 ➝ $10.00Low
11/15/2022Maxim GroupLower Target$8.00 ➝ $5.00Low
12/22/2021Dawson JamesReiterated RatingNeutralMedium
2/4/2021Maxim GroupUpgradeHold ➝ Buy$12.00High
11/17/2020Maxim GroupDowngradeBuy ➝ HoldN/A
7/8/2020Maxim GroupBoost TargetBuy$9.00 ➝ $20.00Low
5/8/2020Maxim GroupInitiated CoverageBuy$9.00Medium
11/15/2019Maxim GroupReiterated RatingBuy$9.00Low
10/11/2019Maxim GroupSet TargetBuy$9.00Low
(Data available from 5/22/2019 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
10/25/2023
  • 3 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
11/24/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2024
  • 2 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/22/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2024

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Brainstorm Cell Therapeutics logo
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Read More

Today's Range

Now: $0.62
Low: $0.57
High: $0.63

50 Day Range

MA: $0.52
Low: $0.33
High: $0.74

52 Week Range

Now: $0.62
Low: $0.13
High: $3.34

Volume

1,027,488 shs

Average Volume

679,580 shs

Market Capitalization

$43.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Brainstorm Cell Therapeutics?

The following Wall Street analysts have issued research reports on Brainstorm Cell Therapeutics in the last twelve months: Maxim Group, and StockNews.com.
View the latest analyst ratings for BCLI.

What is the current price target for Brainstorm Cell Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Brainstorm Cell Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Brainstorm Cell Therapeutics in the next year.
View the latest price targets for BCLI.

What is the current consensus analyst rating for Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BCLI, but not buy more shares or sell existing shares.
View the latest ratings for BCLI.

What other companies compete with Brainstorm Cell Therapeutics?

Other companies that are similar to Brainstorm Cell Therapeutics include Lipocine, LianBio, SAB Biotherapeutics, Acasti Pharma and AVROBIO. Learn More about companies similar to Brainstorm Cell Therapeutics.

How do I contact Brainstorm Cell Therapeutics' investor relations team?

Brainstorm Cell Therapeutics' physical mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company's listed phone number is (201) 488-0460 and its investor relations email address is [email protected]. The official website for Brainstorm Cell Therapeutics is www.brainstorm-cell.com. Learn More about contacing Brainstorm Cell Therapeutics investor relations.